BCL2 and acute myeloid leukemia: BETi was found to be efficient in RUNX1mut AML [174,176], and its association with other drugs induced synergic blasts lethality, notably with the JAK inhibitor ruxolitinib [171] and the anti-BCL2 agent venetoclax [176].